Cheryl is an experienced leader with a proven track record in developing strategy, driving commercial growth, and catalyzing talent excellence. She is currently an independent, Non-Executive Board Director at Allergy Therapeutics plc (LON:AGY), a pioneering immunology business with specialized focus on the research, development and commercialization of allergy treatments. She chairs the Remuneration Committee and is a member of the Audit & Risk and Nomination Committees.

Previously in the UK at ViiV Healthcare, a purpose-powered company dedicated to eradicating HIV with a mission to leave no person living with HIV behind, Cheryl set global strategy, ensuring access to medicines through a new wave of transformative medicines for the 38 million people around the world living with HIV, and modernizing the customer experience through digital engagement. Whilst in the US at GSK, Cheryl had P&L accountability >$4B USD with teams of up to 3000 employees and leadership of US operations where she drove game-changing moves that pivoted a business trajectory, launched new medicines, and surpassed external benchmarks in employee engagement. She turned around a business in crisis, returned the US business to growth, gained share, and outpaced the market. Cheryl began her pharma career at GSK in Canada with roles across Medical, Marketing and Sales, modernizing customer engagement for accelerated growth across a broad range of medicines and vaccines.

Cheryl holds a Degree in Pharmacy from the University of Toronto, a Masters, Business Administration from the Schulich School of Business, York University in Toronto, and executive/non-executive development from Harvard, Rotman, Wharton and Columbia.